^
    1d
    adIVO: Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P2 trial
    |
    Tibsovo (ivosidenib)
    8d
    Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Institut de Recherches Internationales Servier (I.R.I.S.)
    New P1 trial
    |
    Voranigo (vorasidenib)
    8d
    IVOOBS: OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, French Innovative Leukemia Organisation | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    Tibsovo (ivosidenib)
    14d
    VIOLETA: Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, iOMEDICO AG
    New trial
    |
    Voranigo (vorasidenib)
    15d
    Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=28, Recruiting, Institut de Recherches Internationales Servier (I.R.I.S.)
    New P1 trial
    |
    Voranigo (vorasidenib) • midazolam hydrochloride
    15d
    A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (clinicaltrials.gov)
    P1, N=28, Recruiting, Institut de Recherches Internationales Servier (I.R.I.S.)
    New P1 trial
    |
    Voranigo (vorasidenib)
    16d
    Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed IDH1 mutant AML. (PubMed, Future Oncol)
    ALIDHE represents, to our knowledge, the first AML clinical trial that involves patient representatives from development of the study concept to follow-up. ALAN will continue to be involved in ALIDHE as part of the patient steering committee, to ensure that patient perspectives and needs continue to be considered throughout the study duration.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    azacitidine • Tibsovo (ivosidenib)
    17d
    Integration and Intersection of Cancer Metabolism with Epigenetic Pathways in Gliomas. (PubMed, Annu Rev Pathol)
    Inhibiting IDH mutations with vorasidenib lowers D-2HG and is beneficial to patients. Other drugs like ONC201 and metformin can metabolically suppress oncogenic chromatin states in pediatric gliomas. This dynamic cross talk between metabolism and epigenetics not only underpins tumor biology but also presents opportunities for innovative therapeutic strategies.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • IDH wild-type
    |
    metformin • Voranigo (vorasidenib) • Modeyso (dordaviprone)
    19d
    ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia. (PubMed, Future Oncol)
    The impact of ivosidenib + azacitidine treatment on health-related quality of life, healthcare resource utilization and measurable residual disease will also be assessed. NCT05907057 (ClinicalTrials.gov).
    P3 data • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    azacitidine • Tibsovo (ivosidenib)
    20d
    Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort. (PubMed, J Hematol Oncol)
    These 5-year data support the durable efficacy and manageable safety profile of olutasidenib in R/R mIDH1 AML, including heavily pretreated patients. Findings highlight the potential role of olutasidenib in earlier lines of treatment, and support sustaining therapy for at least 6 months to allow for a clinical response. Further research is warranted to optimize treatment sequencing and patient selection.
    P2 data • Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH1 R132
    |
    Rezlidhia (olutasidenib)
    24d
    NCI-2021-00893: Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=84, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    Venclexta (venetoclax) • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inqovi (decitabine/cedazuridine)
    24d
    A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations (clinicaltrials.gov)
    P1, N=166, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    IDH1 R132
    |
    IDH305